Launch Timeline: Concept to First Commercial Sale

Most guides on medical devices skip straight from "market opportunity" to "get FDA approval" as if that were a single step. It is not. A heart pump device business runs on a multi-year, milestone-gated timeline where each phase has to be funded before the next one can begin, and lenders or investors will expect your business plan to show exactly where each dollar goes.

Month 1-6: Feasibility & Pre-Submission

• Bench and animal (GLP) testing to establish baseline hemodynamic performance
• Freedom-to-operate patent search given how dense the VAD patent landscape already is
• FDA Q-Submission (pre-submission meeting request) to align on the intended clinical and regulatory pathway
• ISO 13485 quality management system scoping and design controls documentation begins

Month 6-14: Investigational Device Exemption (IDE) Preparation

• Finalize device design freeze and manufacturing process validation
• Build the clinical protocol with a cardiac surgery and heart-failure clinical advisory board
• Submit IDE application; FDA has 30 days to respond before a first-in-human study can begin
• Identify 2-4 investigational sites, typically academic transplant/heart-failure centres

Month 14-30: Clinical Study Execution

• Enroll and follow patients per protocol; short-term circulatory support studies run faster than destination-therapy trials
• Interim safety reviews with the Data Safety Monitoring Board
• Begin the PMA submission modules in parallel (manufacturing, non-clinical, labeling) rather than waiting for trial completion

Month 30-48: PMA Submission & Commercial Launch Prep

• Submit the full PMA application; budget for the $540,783 standard FDA user fee (or $135,196 under the small-business fee schedule)
• Run parallel MHRA/UKCA and EU MDR notified-body conformity assessments if UK/EU launch is planned in year one of commercialisation
• Engage hospital value-analysis committees and payers 6-12 months before approval, not after
• Build post-market surveillance and device registry infrastructure, now a standard condition of approval

This is the single biggest planning mistake we see: founders build a 12-month go-to-market plan for a process that, for a Class III cardiac device, realistically takes 3 to 4 years. A credible plan needs a funding runway that matches this timeline, staged in tranches tied to regulatory milestones rather than one lump-sum ask.

What It Actually Costs to Build This Business

Total capital required to take a heart pump device from prototype through FDA Premarket Approval typically runs $500,000 to $6 million (£400,000 to £4.5 million) depending on device complexity, trial scope, and how much clinical work is outsourced to a contract research organisation versus run in-house. This is a fundamentally different cost structure than most "business plan template" pages assume, because the dominant line items are regulatory and clinical, not marketing or premises.

Cost Breakdown

• Prototype engineering & bench/animal (GLP) testing: $150K-$1.2M (£120K-£950K)
• FDA PMA user fee + regulatory consulting: $135K-$541K (standard 2025 FDA fee schedule)
• MHRA UKCA conformity assessment (UK Approved Body): £60K-£400K
• Clinical investigation / GCP trial costs: $100K-$3M+ (£80K-£2.5M+)
• Quality management system (ISO 13485) build-out: $40K-$180K (£30K-£140K)
• Product liability & clinical trial insurance: $25K-$150K/yr (£20K-£120K/yr)
• Working capital (12-18 months pre-revenue): $80K-$700K (£60K-£550K)

Funding Routes That Actually Work Here

Very few heart pump device startups fund this journey from a single source. The pattern we see in well-structured plans combines non-dilutive SBIR/STTR Phase I and Phase II grants (typically $250K-$2M combined, awarded by NIH or the National Heart, Lung, and Blood Institute) with a seed or Series A round from a medtech-focused venture fund such as SV Health Investors, LRVHealth, or Third Rock Ventures. In the UK, Innovate UK smart grants and NHS Small Business Research Initiative contracts play a similar non-dilutive role alongside private angel or venture capital. Strategic partnerships or licensing deals with an established device manufacturer are also common exit or co-development routes once first-in-human data exists.

Staging the Raise to the Regulatory Timeline

A financial model built for a Class III cardiac device should never present a single lump-sum funding ask. Investors and grant reviewers expect to see capital staged against milestones, both because it reduces their risk and because it forces the founding team to be explicit about what each tranche actually buys. A typical staging pattern looks like a pre-seed or seed tranche of $500,000 to $1.5 million to fund bench testing, GLP animal studies, and the FDA pre-submission meeting; a Series A tranche of $2 million to $4 million to fund IDE-enabling work and the first-in-human feasibility study; and a Series B or growth tranche of $3 million to $8 million or more to fund the pivotal trial and PMA submission itself, often overlapping with early UK/EU conformity assessment work if a multi-jurisdiction launch is planned. Structuring the ask this way, with clear go/no-go criteria between tranches, is one of the clearest signals to a medtech investor that the founding team has actually run, or closely studied, a device development program before.

It is also worth budgeting explicitly for the cost of raising each tranche. Specialist medtech due diligence is slower and more technical than a typical software fundraise; expect 4-8 months from first investor conversation to close for an institutional round in this category, and build that timeline into your runway assumptions rather than assuming funds land the month you need them.

Component Suppliers & Manufacturing Partners

A heart pump device is only as reliable as its weakest sourced component. Most independent developers do not manufacture every subsystem in-house; they qualify specialist suppliers for the highest-risk components and keep final assembly and testing internal to protect design control and traceability under ISO 13485.

• Precision motor & rotor assemblies: specialist micro-motor manufacturers experienced in implantable-grade tolerances
• Biocompatible materials (titanium, medical-grade polymers): ASTM F136/F899-certified material suppliers with full material traceability documentation
• Percutaneous lead & driveline components: suppliers with existing FDA Master Access Files to shorten your own submission review
• Battery & external controller electronics: medical-grade battery manufacturers with IEC 60601 certification
• Contract sterilization services: ethylene oxide or gamma sterilization providers validated to ISO 11135/11137
• Contract research organisation (CRO): for GLP animal studies and clinical trial management, ideally one with prior cardiovascular device experience
• Notified/Approved Body: for UKCA and EU MDR conformity assessment, selection should happen in parallel with FDA strategy, not after

Build supplier qualification into your business plan's operations section with named backup suppliers for every single-source component. Reviewers and investors specifically look for supply-chain redundancy on Class III devices, because a single supplier failure can halt a clinical trial or a commercial product recall entirely.

Supplier agreements for implantable device components typically take longer to negotiate than founders expect, particularly around liability allocation and access to the supplier's own FDA Device Master File data, which your regulatory team needs cross-reference rights to in your own submission. Build 3-6 months into your plan for supplier qualification and contracting alone, running in parallel with prototype development rather than sequentially after a design is finalised. A plan that shows supplier contracts already in motion, even if not yet signed, is materially more credible to a diligence-savvy investor than one that treats sourcing as a future to-do item.

Regulatory Pathway: US, UK & EU

United States, FDA

• Heart pump devices are Class III and require Premarket Approval (PMA), the FDA's most rigorous pathway
• Standard PMA user fee: $540,783 (2025 fee schedule); small-business fee: $135,196
• An Investigational Device Exemption (IDE) is required before any first-in-human study; FDA has 30 days to respond
• FDA targets a 45-day acceptance review and a 180-day decision, but real-world PMA timelines commonly run 12-24 months
• Manufacturing facility inspection under the Quality System Regulation is a condition of approval

United Kingdom, MHRA

• Implantable cardiac devices are Class III under UK medical device regulations
• Requires UKCA marking via conformity assessment from a UK Approved Body, mandatory notified-body involvement for Class III
• Certification (UKCA) must complete before MHRA registration; both steps are required before market placement in Great Britain
• FDA clinical and technical data can support the UK submission but does not substitute for it

European Union, MDR 2017/745

• Implantable cardiac devices including VADs are classified Class III under EU MDR, the same tier as pacemakers and prosthetic heart valves
• Mandatory Notified Body conformity assessment plus a published Summary of Safety and Clinical Performance (SSCP) on EUDAMED
• Pre-market clinical investigation is generally required unless full device equivalence can be demonstrated
• Legacy Class III cardiac devices must hold an MDR certificate by 31 December 2027 under Regulation (EU) 2023/607

Building One Regulatory Strategy, Not Three

The single biggest planning error we see in cross-border medtech business plans is treating FDA, MHRA, and EU MDR as three separate projects run by three separate teams. The efficient approach is to design your non-clinical testing, biocompatibility data, and clinical protocol once, built to satisfy the most stringent of the three regimes' requirements, then adapt the administrative wrapper (the PMA submission, the UKCA technical file, the EU MDR technical documentation) around that common evidence base. This typically saves 30-40% of total regulatory-affairs spend compared with running three independent programmes, and a business plan that shows this sequencing explicitly signals to reviewers that the founding team has genuine multi-jurisdiction regulatory experience rather than a US-only playbook.

Pricing, Reimbursement & Margins

Revenue in this category is not a simple retail price. Durable implantable LVAD systems are commonly reimbursed in the $150,000-$250,000 range per device-and-procedure episode in the US under diagnosis-related group (DRG) hospital billing codes, while temporary percutaneous support devices in the Impella style are billed per-procedure, typically in the $25,000-$35,000 range. In the UK, NHS procurement runs through tariff and Healthcare Resource Group (HRG) banding, commonly landing between £60,000 and £120,000 per implant episode.

Worked Example

A device maker selling 40 implantable units in its second commercial year at an average net device price of $95,000 (after distributor and hospital negotiated discounts) generates $3.8 million in device revenue. At a 45% gross margin after manufacturing, sterilization, and warranty reserve, that produces $1.71 million gross profit before R&D amortization and regulatory-affairs overhead, which typically consumes 25-35% of revenue in the first three commercial years for a company still running post-approval studies.

Margin Range

Once a device clears approval and reimbursement coding is established, gross margins on the device itself commonly sit between 40% and 55%. After overhead, net margins for an early-commercial-stage heart pump device company typically fall between 20% and 53%, with the spread reflecting how much R&D spend is still being expensed versus capitalized, and whether the company has reached the volume needed to absorb fixed regulatory-affairs and quality costs.

Why Revenue Ramps Slowly Even After Approval

A common mistake in first-draft financial models is assuming that FDA approval flips revenue on like a switch. In practice, three separate adoption curves have to move in sequence before volume shows up on the income statement. First, hospital value-analysis committees have to formally add the device to approved purchasing lists, a process that can take 3-9 months per institution even after national reimbursement coding exists. Second, individual cardiac surgeons and structural heart teams need proctoring and case volume before they will use a new device as a default rather than an exception, typically 8-15 proctored cases per site before independent use begins. Third, payer-side prior authorization processes lag behind CMS coding decisions, particularly for commercial insurers who may take an additional 6-12 months to update policy after Medicare sets a precedent.

A credible plan therefore models a stepped ramp: a handful of reference sites in year one generating modest volume, expansion to 15-25 active sites by year two, and broader distribution only from year three onward once clinical registries accumulate enough real-world outcome data to support broader committee approvals. Modeling flat, immediate adoption is one of the fastest ways to lose credibility with a sophisticated medtech investor or lender, because it signals the founder has not run a device launch before.

Distribution Model Choices

Most heart pump device companies choose between three go-to-market structures, each with different margin and capital implications. A direct sales model with an employed clinical specialist team offers the highest gross margin retention (the full 40-55% device margin flows through) but requires significant working capital to build a field team ahead of meaningful revenue, commonly $80,000-$150,000 fully loaded per territory manager per year. A distributor model trades 15-30 percentage points of margin for faster geographic coverage and lower fixed cost, which is often the right choice for a company that has not yet raised a large commercial-stage round. A strategic co-marketing or licensing arrangement with an established cardiovascular device company (similar to how many smaller device makers eventually route through partners like Abbott or Johnson & Johnson MedTech's channel) sacrifices the most margin but removes almost all of the commercial build-out cost and risk, and is a realistic outcome path worth including as an alternative scenario in your financial model rather than treating direct sale as the only option.

Market Size & Where Demand Is Growing

Estimates of the global heart pump device market vary by scope and methodology, which is itself worth noting in your plan's market-sizing section, investors will ask which definition you are using. Future Market Insights values the broader heart pump device market at approximately $4.8 billion in 2025, rising to $5.5 billion in 2026. Looking further out, Spherical Insights projects growth from $3 billion in 2025 to $12.24 billion by 2035, a 15.1% CAGR.

Within that market, the ventricular assist device (VAD) segment specifically was valued at $1.49 billion in 2025, projected to reach $1.65 billion in 2026 and $4.25 billion by 2034, according to Fortune Business Insights. Left ventricular assist devices (LVADs) account for roughly 69.7% of the product segment, reflecting the much larger population of chronic heart-failure patients relative to those needing a total artificial heart or short-term percutaneous support.

Consolidation is already reshaping who a new entrant competes against. Abbott Laboratories leads the durable, implantable LVAD segment with its HeartMate 3 system following Medtronic's withdrawal of the HVAD from the market. Abiomed, now operating as part of Johnson & Johnson MedTech following the December 2025 acquisition, dominates temporary percutaneous circulatory support through its Impella product line, deployed across more than 2,500 US hospitals. Smaller, more specialised developers including Berlin Heart, BiVACOR, and Calon Cardio-Technology are targeting paediatric and next-generation total artificial heart niches that the two market leaders have not fully addressed, often the more realistic entry point for an independent startup than competing head-on for the adult destination-therapy LVAD market.

Regional Demand Patterns

The United States remains the largest single market for heart pump devices, driven by the highest global rate of advanced heart-failure diagnosis, the broadest transplant-centre network, and CMS reimbursement pathways that, while slow, are more established than most other jurisdictions'. Western Europe follows, with Germany and the UK representing the two largest single-country markets on the continent, Germany in part because of Berlin Heart's domestic manufacturing and clinical base, and the UK because NHS specialist heart-failure centres in London, Manchester, and Birmingham perform a disproportionate share of the country's advanced mechanical circulatory support procedures. Japan and South Korea are smaller in absolute volume but show some of the fastest adoption growth rates as both countries expand reimbursement for destination-therapy LVAD implants in aging populations. For a founder choosing a first commercial market, the practical decision usually comes down to where your clinical trial sites and advisory board relationships already exist, since regulatory and payer relationships in this category are built over years, not won through a generic market-entry plan.

A second, less obvious growth vector is temporary percutaneous support expanding beyond cardiac catheterization labs into emergency department and cardiac-surgery-adjacent settings, following the pattern Abiomed's Impella line established. Any founder building a plan around a short-term support device should explicitly model this site-of-care expansion as a second wave of growth beyond the initial cath-lab launch, because it materially changes both the sales force structure needed and the device's design requirements around ease of use for non-specialist staff.

Operations Plan & Common Mistakes

The operations section of a heart pump device business plan carries more weight with investors and regulators than the equivalent section in most other industries, because manufacturing quality is directly tied to patient safety and therefore to regulatory approval itself. A weak operations plan is one of the fastest ways to stall a funding conversation with a specialist medtech investor, since they will read this section first to judge whether the founding team actually understands what a Class III device business requires operationally, not just clinically.

What a Credible Operations Plan Covers

• Design controls under 21 CFR 820.30, a documented, auditable trail from user needs through design verification and validation
• Manufacturing site strategy, whether initial production happens in-house, at a contract manufacturer, or a hybrid, and how that scales past the first 50-100 units
• Supplier qualification and control, named primary and backup suppliers for every single-source component, with qualification status noted
• Post-market surveillance plan, how adverse events, complaints, and long-term device performance data will be captured and reported to FDA, MHRA, and EU regulators
• Complaint handling and corrective/preventive action (CAPA) process, required under both FDA QSR and ISO 13485

Five Mistakes That Sink Heart Pump Device Plans

• Underestimating total capital and running out of runway mid-trial, a plan that funds only the next regulatory milestone rather than the full pathway to approval invites a down round or a stalled study when the next tranche doesn't materialise on schedule
• Treating FDA, MHRA, and EU MDR pathways as interchangeable, each requires its own technical file, clinical evidence package, and timeline; a plan that assumes one submission "covers" all three jurisdictions will be flagged immediately by any regulatory-literate reviewer
• Building the reimbursement strategy only after device approval, engaging payers and hospital value-analysis committees during the trial phase, not after PMA approval, is what separates a fast commercial ramp from a slow one
• Underinvesting in the ISO 13485 quality management system early, retrofitting a QMS after a design freeze is significantly more expensive than building it in from the first prototype, and notified-body auditors will scrutinise QMS maturity closely
• Failing to budget for post-market surveillance and device registries, both US and EU regulators now expect ongoing real-world evidence collection as a condition of continued approval, and this is a recurring operating cost many founders leave out of year-three-plus forecasts entirely

Framing the Investor Pitch

Specialist medtech investors read hundreds of cardiovascular device pitches a year, and the ones that stand out are specific about milestone economics rather than broad about market size. A fill-in-the- blanks framing that works well in the executive summary of a bespoke plan looks like this:

What makes this framing work is that every claim is falsifiable and dated. Investors in this category are underwriting execution risk against a known regulatory clock, not a vague market opportunity, so the strongest pitches replace adjectives ("revolutionary," "breakthrough") with named milestones, named comparator devices, and a funding ask sized to a specific next step rather than a round number. A bespoke Avvale plan builds this narrative alongside a financial model that shows exactly how the raise bridges to the next value-inflection point, whether that is IDE clearance, first-in-human data, or PMA submission.

Questions Founders Ask Before They Start

Is it realistic to compete with Abbott and Abiomed as an independent startup?

Direct competition for the adult chronic-therapy LVAD market is extremely difficult given the scale and clinical evidence base Abbott has built. The more realistic path for a new entrant is a narrower clinical niche, paediatric support, a specific short-term percutaneous use case, or a next-generation total artificial heart design, where the incumbents have gaps, followed by a strategic partnership or acquisition once first clinical data exists.

What's the difference between 510(k) and PMA for a device like this?

A 510(k) clearance requires showing "substantial equivalence" to an existing legally marketed device and is far faster and cheaper. Because heart pump devices sustain or support life and carry significant risk, they are classified Class III and almost always require the full PMA pathway rather than 510(k), even when a broadly similar predicate device exists.

How do reimbursement codes get assigned to a brand-new device category?

Sponsors typically work with CMS during the PMA review process to secure a New Technology Add-on Payment (NTAP) or an appropriate DRG assignment ahead of commercial launch. This process should start 12 months or more before expected approval, not after, a gap many first-time device founders underestimate.

Do I need a US entity if I'm developing the device in the UK or EU?

Not necessarily to develop the device, but you will need either a US-based entity or a US Agent to correspond with the FDA once you file a PMA, and most investors will expect a Delaware C-corp or similar structure if you plan to raise US venture capital alongside any UK/EU funding.

Sample Business Plan Preview

Here's an extract from the kind of executive summary our team writes for a heart pump device company, so you can see exactly what you'll get:

What's in the Template

Every Avvale business plan template includes these sections, pre-structured for your industry:

• Executive Summary, Your device and company at a glance, written to hook investors in 60 seconds
• Company Overview, Legal structure, IP position, and founding team
• Industry Analysis, Market size, growth trends, and the regulatory landscape specific to your device class
• Customer & Clinical Analysis, Target patient population, referring physicians, and hospital purchasing pathways
• Competitor Analysis, Named competitor mapping and where your device differentiates clinically and commercially
• Regulatory & Clinical Plan, Milestone-gated pathway across FDA, MHRA, and EU MDR
• Operations Plan, Manufacturing, supplier qualification, and quality-system milestones
• Management Team, Founder bios, clinical advisory board, and key hires planned

The optional Financial Forecast add-on (included in our $300/£250 and $1,000/£800 packages) provides a 5-year Excel model with milestone-tranche funding requirements, cash flow, and break-even analysis calibrated to a multi-year regulatory timeline rather than a generic 12-month startup model.

Because this template is built specifically for regulated medical device businesses, it also differs from Avvale's general-purpose templates in a few structural ways: the milestone/funding-tranche framework replaces a standard month-by-month operating budget, the regulatory section is expanded to cover three jurisdictions rather than a single licensing checklist, and the competitor analysis section is built around named device manufacturers and clinical evidence comparisons rather than local market-share estimates. If your concept sits closer to a digital health tool, a diagnostic service, or a clinic-based business than an implantable or invasive device, our general healthcare business plan resources may be a better structural fit; if you are building a Class II or Class III hardware device, this template's structure is built around exactly that funding and regulatory reality.

Frequently Asked Questions